Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT03286530
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib. After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment.

Study Details

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib

Key Dates

Start date
Nov 3, 2017
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
64 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.

Primary Outcome Measure

1-year GVHD/relapse free survival rate (GRFS rate) [ Time Frame: 1 Year ]

Locations (6)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02115-
Washington UniversitySt LouisMissouri63130-
The Ohio State UniversityColumbusOhio43210-
Vanderbilt UniversityNashvilleTennessee37235-
Medical College of WisconsinWauwatosaWisconsin53226-

Find similar trials in Boston, MA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Beth Israel Deaconess Medical Center· Boston, MAMassachusetts General Hospital· Boston, MAWashington University· St Louis, MOThe Ohio State University· Columbus, OHVanderbilt University· Nashville, TNMedical College of Wisconsin· Wauwatosa, WI

Related Studies